Formycon Believes Itself Among Frontrunners For Mammoth Keytruda Opportunity
German Firm Distances Comparisons With Saturated Humira Development Pool
On the back of early success with its biosimilar to Lucentis (ranibizumab), Formycon has looked further into the future and divulged details on the set-to-be competitive race to develop a biosimilar to Merck & Co’s €10bn ($10.9bn) PD-1 inhibitor Keytruda (pembrolizumab).
